Imprimis Pharmaceuticals Announces First Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Imprimis Pharma (IMMY) Reports Q1 Revenues Above Estimates
May 15, 2018 4:02 PM EDTImprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of $, versus $0.00 reported last year. Revenue for the quarter came in at $8.9 million versus the consensus estimate of $6.86 million.
Notable Highlights:
Revenue of $8.9 million, up 45% year-over-yearGross ophthalmology-related revenue of $7.0 million, up 91%... More